Cited by 275

Artificial intelligence in lung cancer diagnosis and prognosis: Current application and future perspective

Huang, Shigao, Yang, Jie, Shen, Na, Xu, Qingsong, Zhao, Qi·2023·Seminars in Cancer Biology

Abstract

Lung cancer is one of the malignant tumors with the highest incidence and mortality in the world. The overall five-year survival rate of lung cancer is relatively lower than many leading cancers. Early diagnosis and prognosis of lung cancer are essential to improve the patient's survival rate. With artificial intelligence (AI) approaches widely applied in lung cancer, early diagnosis and prediction have achieved excellent performance in recent years. This review summarizes various types of AI algorithm applications in lung cancer, including natural language processing (NLP), machine learning and deep learning, and reinforcement learning. In addition, we provides evidence regarding the application of AI in lung cancer diagnostic and clinical prognosis. This review aims to elucidate the value of AI in lung cancer diagnosis and prognosis as the novel screening decision-making for the precise treatment of lung cancer patients.

Integrity signals

Registry

Crossref · 10.1016/j.semcancer.2023.01.006

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Integrating multiple biomarkers such as HE4, sVCAM-1, TTR, ApoA2, and CEA can markedly enhance diagnostic performance; one such model reached a sensitivity of 93.33%, specificity of 92.00%, and an AUC of 0.988.

    “Additional studies have reported that integrating multiple biomarkers—such as human epididymis protein 4 (HE4), soluble vascular cell adhesion molecule-1 (sVCAM-1), transthyretin (TTR), apolipoprotein A2 (ApoA2), and the carcinoembryonic antigen CEA—can markedly enhance diagnostic performance. One such model reached a sensitivity of 93.33%, specificity of 92.00%, and an AUC of 0.988, indicating”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Huang, S., Yang, J., Shen, N., Xu, Q., & Zhao, Q.
Venue
Seminars in Cancer Biology
Publisher
Elsevier BV
Published
2023-02
Volume
89
Pages
30-37
ISSN
1044-579X
Cited by
275
References
5
Language
en
Funders
  • Natural Science Foundation of Chongqing (cstc2021jcyj-msxmX1108)
  • National Key Research and Development Program of China (2019YFA0904400)
  • Ministry of Education of the People's Republic of China
  • Shanghai Science and Technology Development Foundation
  • Science and Technology Planning Project of Shenzhen Municipality (SGDX2020110309280301)
  • Universidade de Macau (MYRG2022-00143-FHS, MYRG2019-00069-FHS)
  • Shenzhen Science and Technology Innovation Commission
  • Chongqing Municipal Education Commission (KJQN0202203602, KJQN202203607, KJZD-K202203601)
  • Humanities and Social Science Fund of Ministry of Education of the People's Republic of China (22YJCZH213)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review